

Luca Potestio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9588903/publications.pdf>

Version: 2024-02-01

40
papers

760
citations

567281

15
h-index

713466

21
g-index

40
all docs

40
docs citations

40
times ranked

106
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2813-2820.	2.2	57
2	Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2560-2564.	2.2	43
3	Risankizumab treatment in psoriasis patients who failed anti-IL17: A 52-week real-life study. <i>Dermatologic Therapy</i> , 2022, 35, e15524.	1.7	43
4	The Treatment of Advanced Melanoma: Therapeutic Update. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6388.	4.1	41
5	Reply to "Psoriasis exacerbation after COVID-19 vaccination: report of 14 cases from a single centre" by Sotiriou E <i>et al</i> .. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	40
6	Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1497-1498.	2.4	37
7	Scabies outbreak during COVID-19: an Italian experience. <i>International Journal of Dermatology</i> , 2021, 60, 1307-1308.	1.0	34
8	Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. <i>Journal of Clinical Medicine</i> , 2022, 11, 1511.	2.4	34
9	Teledermatology: A useful tool also after COVID-19 era?. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 2309-2310.	1.6	33
10	New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?. <i>Biomedicines</i> , 2021, 9, 1482.	3.2	31
11	Treating psoriasis in the elderly: biologics and small molecules. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 1503-1520.	3.1	30
12	New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma. <i>Advances in Therapy</i> , 2022, 39, 1164-1178.	2.9	29
13	Atopic dermatitis exacerbation after Covid-19 vaccination in Dupilumab-treated patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	28
14	Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single-center retrospective study in a real-life setting. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	28
15	Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?. <i>Dermatologic Therapy</i> , 2021, 34, e15030.	1.7	27
16	New-onset lichen planus arising after COVID-19 vaccination. <i>Dermatologic Therapy</i> , 2022, 35, e15374.	1.7	27
17	Reply to "Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study"™ by Bawane J <i>et al</i> .. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	27
18	Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis. <i>Dermatologic Therapy</i> , 2021, 34, e15120.	1.7	25

#	ARTICLE	IF	CITATIONS
19	Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 12, 127-137.	2.2	24
20	Dupilumab for the treatment of adult atopic dermatitis in special populations. <i>Journal of Dermatological Treatment</i> , 2022, 33, 3028-3033.	2.2	23
21	Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 21-29.	2.4	21
22	A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis. <i>Dermatologic Therapy</i> , 2022, 35, e15588.	1.7	15
23	Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 12, 205-212.	2.2	15
24	Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study. <i>Psoriasis: Targets and Therapy</i> , 0, Volume 12, 199-204.	2.2	7
25	Letter to the editor regarding article "Yalici Armagan B, Tabak GH, Dogan Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. <i>J Cosmet Dermatol</i> . 2021;00:1-5, <i>Journal of Cosmetic Dermatology</i> . 2021, 20, 4073-4075.	1.6	6
26	Alitretinoin for the treatment of severe chronic eczema of the hands. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 159-167.	1.8	6
27	Maskne prevalence and risk factors during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	5
28	A case of acne fulminans successfully treated with photodynamic therapy. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2022, 38, 401-403.	1.5	4
29	Letter to the editor submitted in response to "Should the presence of psoriatic arthritis change how we manage psoriasis?". <i>Journal of Dermatological Treatment</i> , 2022, , 1-3.	2.2	3
30	Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas. <i>Oncologist</i> , 2022, 27, e533-e533.	3.7	3
31	Acrodermatitis continua of Hallopeau: Is apremilast an efficacious treatment option?. <i>Dermatologic Therapy</i> , 2022, 35, e15423.	1.7	3
32	Clinical, trichoscopic and <i>in vivo</i> reflectance confocal microscopy evaluation of alopecia areata in atopic dermatitis patients treated with dupilumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	3
33	Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops. <i>Contact Dermatitis</i> , 2021, 85, 382-384.	1.4	2
34	Dermatophytid evaluated by <i>in vivo</i> reflectance confocal microscopy: a new approach?. <i>International Journal of Dermatology</i> , 2022, , .	1.0	2
35	Letter to the editor regarding the article "Oguz Topal I, Kara Polat A, Zindanc A, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. <i>J Cosmet Dermatol</i> . 2021;10.1111/jocd.14610. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 880-882.	1.6	2
36	Adalimumab biosimilar in a pediatric patient: Clinical and <i>in vivo</i> reflectance confocal microscopy evaluation. <i>Dermatologic Therapy</i> , 2022, 35, .	1.7	2

#	ARTICLE	IF	CITATIONS
37	Alcohol flushing during dupilumab therapy: An emerging adverse event. <i>Dermatologic Therapy</i> , 2021, 34, e15064.	1.7	0
38	The effects of dupilumab treatment on general health-related work productivity of adult atopic patients. <i>Italian Journal of Dermatology and Venereology</i> , 2022, , .	0.2	0
39	Letter to the editor regarding article “Gu L, Diaz SM, Lipner SR. Retrospective study of acne telemedicine and in-person visits at an academic center during the COVID-19 pandemic. <i>JACosmet Dermatol.</i> 2022;21(1):36-38.” <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 6441-6442.	1.6	0
40	Letter to the editor submitted in response to “Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study” TM . <i>Journal of Dermatological Treatment</i> , 0, , 1-2.	2.2	0